National Pharmacare Hasn’t Reached Ontario. Why Employers Should Prepare Anyway

For an Ontario benefits plan sponsor, the most important fact about national pharmacare is the one that has not happened: As of August 2026, Ontario has not signed an agreement to participate. That means Ontario employers should not currently expect diabetes and contraceptive claims to move from their workplace plans to the new federal-provincial pharmacare model. There is no immediate pharmacare saving to build into an Ontario benefits budget.

The developments elsewhere still matter. They show how a future public program could change which payer receives a drug claim and why employers will need reliable data before deciding whether lower claims justify lower premiums or changes to plan design.

Pharmacist assisting customer with prescription.

Ontario is outside the first phase

The federal Pharmacare Act came into force on October 10, 2024. Its first phase supports universal, single-payer, first-dollar coverage for ranges of diabetes medications and contraceptives through agreements with participating provinces and territories.

As of August 17, 2026, Health Canada lists four agreements: British Columbia, Manitoba, Prince Edward Island and Yukon. Ontario is not on the list.

In those jurisdictions, eligible products are generally paid through the public program at the pharmacy counter rather than coordinated with a private drug plan. The formularies, eligibility conditions, implementation dates and coverage of diabetes devices and supplies vary.

This gives Ontario employers an early view of the questions that could arise if the province signs a future agreement. It does not establish whether Ontario will participate, when it might do so or whether its program would match another province’s approach.

Ontario already has a public-private drug coverage boundary

National pharmacare would not be introduced into an empty space. Ontario already has several public drug programs, and their interaction with workplace coverage is not always straightforward.

• The Ontario Drug Benefit program covers eligible groups such as seniors, social-assistance recipients, certain home-care clients and people enrolled in the Trillium Drug Program. Coverage depends on eligibility, the provincial formulary and, for some medications, clinical criteria.

• OHIP+ covers eligible Ontario residents aged 24 and younger only when they do not have private drug coverage. Once a person has access to a workplace plan, they are generally no longer eligible for OHIP+.

• The Trillium Drug Program can assist households whose prescription costs are high relative to income and whose private insurance does not pay the full cost. Private-plan payments do not count toward the household’s Trillium deductible.

These distinctions already affect who pays, what reaches the employer plan and what remains out of pocket. Before looking ahead to national pharmacare, plan sponsors should understand whether their current insurer is applying Ontario’s existing public coverage rules correctly.

Build the baseline before the policy changes

A future Ontario agreement would create a before-and-after measurement problem. Employers will get a better answer if they establish the “before” picture now.

Ask for aggregated drug claims data that can be examined by:

• Therapeutic class and, where available, Drug Identification Number

• Plan-paid amount, eligible amount and prescription count

• Number of claimants, kept separate from cost per claimant

• Claimant age bands, where group size and privacy standards permit

• Diabetes medications, contraceptives and related devices or supplies

• Claims coordinated with an existing public program

• Rejected or redirected claims and the associated reason codes

• Brand-name drugs, special-authorization products and lower-cost alternatives

• Claims included in the employer’s experience compared with claims affected by pooling

The purpose is not to identify employees or their medical conditions. It is to understand the plan’s current financial exposure to drug categories that could eventually move, in whole or in part, to public coverage.

An Ontario employer with employees in British Columbia, Manitoba, Prince Edward Island or Yukon should request the same analysis by province. Those organizations may already have a measurable payer shift within part of their workforce, even though their head office and most employees are in Ontario.

Put Ontario’s current rules on the renewal agenda

Plan sponsors do not need to wait for an Ontario pharmacare announcement to ask better questions. At the next renewal, ask the insurer or advisor:

• How does the plan currently coordinate with Ontario Drug Benefit and Trillium?

• How does the insurer identify dependants who are ineligible for OHIP+ because they have private coverage?

• Which drug claims are included in our experience, and which are removed or modified through pooling?

• Can we see diabetes medication and contraceptive claims separately from the rest of the drug category?

• If Ontario introduced first-dollar public coverage for specified medications, which of our historical claims would likely have moved?

• How would a reduction in those claims affect the renewal calculation?

• Would any change be reflected immediately, or only after enough credible claims experience had developed?

• What private coverage might still be required for products outside a public formulary, brand-price differences, devices or special-authorization drugs?

The answers should distinguish actual Ontario claims from modelling based on other provinces. A scenario can support planning, but it should not be presented as a forecast or promised saving.

Why future public coverage may not produce equal plan savings

If Ontario eventually pays for drugs that currently appear in private claims, employer costs could decline. The reduction would not necessarily match the value of the claims transferred.

Some affected medications may already be paid publicly or out of pocket. The claims may be a modest part of the overall extended-health benefit. Renewal pricing can also reflect expected trend, the credibility of the group’s experience, insurer expenses, taxes and pooling charges—not only the most recent paid claims.

Timing will matter. A program introduced partway through an experience period may produce only a partial-year change. A high-cost claim removed from the employer’s experience may have already been protected by pooling, limiting its direct effect on the renewal.

Plan sponsors should therefore ask two separate questions:

1. How much cost actually left the plan?

2. How did the insurer reflect that change in the renewal rate?

Watch for the decisions that would change the analysis

For Ontario employers, the important triggers would be:

• A federal-Ontario pharmacare agreement

• A confirmed implementation date

• The final list of covered drugs and products

• Eligibility and clinical requirements

• Rules identifying the public program as first payer

• Treatment of brand-name products, devices and supplies

• Insurer confirmation that claims systems have been updated

• Enough post-implementation experience to measure the effect

Until those details exist, removing private coverage would be premature. Over time, verified public coverage could create opportunities to eliminate genuine duplication or redirect demonstrated savings to other benefits priorities. Any redesign would still need to account for employees outside Ontario, people who move between provinces and medications that remain outside the public formulary.

Ontario employers do not have a national pharmacare saving to capture today. They do have an opportunity to improve the quality of their drug-plan data and renewal conversations. That preparation will make the eventual financial impact, if Ontario joins, much easier to identify and much harder to overstate.